课题基金 / 基金详情

Prevention of Skin Cancer by Scutellaria Baicalensis

Prevention of Skin Cancer by Scutellaria Baicalensis
黄芩预防皮肤癌
批准号:
6766005
负责人:
HUACHEN WEI
金额:
$35.57万
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-09-18 至 2006-06-30

项目摘要

项目成果

HUACHEN WEI的其他基金

相似基金

相关文献

中文摘要
翻译
中草药黄芩具有多种抗炎、抗癌活性。这一建议的中心假设是黄芩提取物(SBE)抑制紫外线(UV)B诱导的嘧啶二聚体和DNA氧化损伤,并调节UVB激活的信号转导级联和炎症反应,从而抑制光致癌的启动和促进。该项目的最初目标是确定SBE在使用前或使用后是否可以预防UVB诱导的皮肤癌。该项目的最初目标是确定SBE在使用前或使用后是否可以预防UVB诱导的皮肤癌。SBE将在暴露于UVB期间局部应用于无毛小鼠。将通过分析潜伏期、肿瘤发生率和多样性来评估保护效果。第二个目的是评估SBE在光致癌的启动、促进和进展中的作用。我们将使用UVB-致癌物联合模型来分析SBE在UBV诱导的皮肤癌变中的抗启动或抗促进作用。SBE将在UVB启动剂量之前局部应用于小鼠皮肤,随后是TPA促进,或在DMBA启动的小鼠UCB照射之前应用。通过记录肿瘤消退率和恶转率来检验SBE对现有皮肤肿瘤的治疗效果。第三个目的是确定SBE是否在体内和体外改变了UVB诱导的与启动和促进相关的中间终点,如DNA光产物、氧化DNA损伤、炎症反应、原癌基因表达和AP-1因子的激活。最后,我们将进一步评估SBE对UVB诱导的红斑和人体皮肤不适的保护作用。DNA损伤(嘧啶二聚体和8-OHdG)、细胞凋亡(P53蛋白表达)和细胞增殖(增殖细胞核抗原)的分子标记物将在人体皮肤活检和长期暴露于UVB的三维重组人皮肤中被确定。这些研究的成功完成不仅将有助于创新地利用草药提取物作为预防和/或治疗人类皮肤癌的药物,而且还将促进Be在其他人类恶性肿瘤中的抗癌作用的研究。
英文摘要
Chinese herbal medicine Huang Qin (Scutellaria baicalensis) has a variety of anti-inflammatory and anti-cancer activities. The central hypothesis of this proposal is that Scutellaria baicalensis extracts (SBE) inhibit ultraviolet (UV) B-induced pyrimidine dimers and oxidative DNA damage, and modulate UVB-activated signal transduction cascades and inflammatory responses, thereby suppressing the initiation and promotion of photocarcinogenesis. The initial aim of the project is to determine if pre- or post-application of SBE prevents UVB-induced skin carcinogenesis. The initial aim of the project is to determine if pre- or post-application of SBE prevents UVB-induced skin carcinogenesis. SBE will be topically applied to hairless mice during exposure to UVB. The protective effect will be evaluated by analyzing the latency period, tumor incidence and multiplicity. The second aim is to evaluated the effects of SBE on the initiation, promotion, and progression of photocarcinogenesis. A combined UVB-carcinogen model will be used to dissect the anti-initiational or anti-promotional effects of SBE on UBV- induced skin carcinogenesis. SBE will be topically applied to mouse skin before an initiating dose of UVB, followed by TPA promotion, or applied before UCB radiation in DMBA-initiated mice. The therapeutic effect of SBE will be tested on the existing cutaneous tumors by recording the tumor regression rate and malignant conversion rate. The third aim is to determine if SBE modifies UVB-induced intermediate endpoints relevant to initiation and promotion, e.g. DNA photoproducts, oxidative DNA damage, inflammatory responses, protooncogene expression and activation of AP-1 factor in vivo and in vitro. Lastly, we will further evaluate the efficacy of SBE in protection of UVB-induced erythema and discomfort in human skin. The molecular markers of DNA damage (pyrimidine dimers and 8-OHdG), apoptosis (p53 protein expression), and cell proliferation (PCNA) will be determined in the human skin biopsies as well as in 3-dimensional reconstituted human skin chronically exposed to UVB. Successful completion of the proposed studies will not only contribute to innovative use of herbal extracts as preventive and/or therapeutic agents against human skin cancer, but also promote the research on the anti-cancer action of BE in other human malignancies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
GENISTEIN IN INVESTIGATIVE AND CLINICAL DERMATOLOGY
GENISTEIN IN INVESTIGATIVE AND CLINICAL DERMATOLOGY
GENISTEIN IN INVESTIGATIVE AND CLINICAL DERMATOLOGY
GENISTEIN IN INVESTIGATIVE AND CLINICAL DERMATOLOGY
海外基金